TABLE 1.

Comparison of cancer surveillance protocol by Villani et al with NCCN^a guidelines by cancer type

Cancer Type	Villani et al protocol9	NCCN10
ACC	US abdomen/pelvis q3 to four months from ages 0–40 Blood tests q3 to four months for 17-OH-proesterone, total testosterone, dehydroepiandrosterone sulfate, and androstenedione values from ages 0 to 40	No specific recommendation, would be included in the recommendation for annual whole-body MRI
Brain tumor	Annual brain MRI beginning at birth	Annual brain MRI
Soft tissue and osteosarcomas	Annualwhole-body MRI US abdomen/pelvis q3 to four months beginning at age 18	Annual whole-body MRI
Breast cancer	Clinical breast exams q6 months beginning at age 20 Annual mammography and breast MRI from ages 20–75 Consider risk-reducing mastectomy	Clinical breast exams q6to 12 months beginning at age 20 Annual breast MRI at ages 20–29 Annual mammogram and breast MRI for ages 30–75 Consider risk-reducing mastectomy
Colorectal	Colonoscopiesq2 years beginning at age 25	Colonoscopies q2 to five years beginning at age 25
Melanoma	Annual dermatology exam beginning at age 18	NA
Leukemia	CBC, erythrocyte sedimentation rate, lactate dehydrogenase q3 to four months	NA
Other	Physical exam q3 to four months from birth	Annual physical exam

^aNational Comprehensive Cancer Network.